Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pituitary Cancer Market size was over USD 418.2 million in 2024 and is estimated to reach USD 1.28 billion by the end of 2037, expanding at a CAGR of 9.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of pituitary cancer is assessed at USD 459.1 million.
The growth of the market can be characterized by the increase in awareness of the type of cancer. Pituitary adenomas account for 15% of intracranial cancer and are usually present in the sellar and suprasellar region, constituting 90% of cases. Pituitary carcinomas are uncommon and spread beyond the pituitary gland, accounting for 0.1%-0.2% of pituitary adenomas. In July 2024, Pharmac proposed to fund lanreotide acetate as a medication to broaden the accessibility of cancer treatment.
The pituitary cancer market is considered to expand based on the evolution of surgical therapy with the implementation of advanced technologies. The Lancet Commission’s Global Surgery 2030 report stated that 5 million globally are devoid of surgical care, either due to oncologic indications or benign. Additionally, the report estimated that 80% of cancer cases require surgery and by 2030, 17.3 million patients will require surgical operations for the treatment and diagnosis of cancer. As per the National Cancer Institute, transsphenoidal surgery is one of the most common surgeries which is necessary if the tumor causes symptoms and presses on nearby structures and can be removed through nasal passage.
Pituitary Cancer Sector: Growth Drivers and Challenges
Growth Drivers
- Expansion of diagnostic imaging: Magnetic resonance imaging scan, known as MRI scan is the most suitable diagnostic for pituitary cancer that utilizes computer-based radio waves and magnetic field to develop images of the size and location of the tumor. For instance, prolactinoma is a chronic pituitary tumor and its prevalence is nearly 1/2,000, accounting for 80% of microadenomas in women and 80% of macroadenomas among men. Besides, radiotherapy is another diagnostic imaging for pituitary cancer not restored by conventional surgery. Regardless of irradiation, the cancer control rate is 90%-95% in 5 years, 80%-94% in 10 years, and 75%-90% in 20 years, hence it is expected to boost the pituitary cancer market in the forecast period.
- Research pursuit and expansion: Metabolic reprogramming is one of the attributes of cancer denoting that mitochondria are necessary for the growth of tumor. Recent research states that it ensures autophagy, energy metabolism, and immune response to understand the pathogenesis of pituitary cancer. Besides, primary brain tumors have pituitary neuroendocrine tumor as their third most common type. Surgical treatment is the foremost treatment, but 10%-20% tumors may reoccur. While dopamine agonists are constructive for over 90% of prolactinomas, individual variations and elongated use result in enhanced drug reluctance and eventual reduction in efficacy to expand research for the pituitary cancer market.
Challenges
- Inappropriate diagnosis and treatment: Interstitial therapy causes failure in the pituitary gland, resulting in growth reduction, delayed puberty, as well as thyroid and adrenal gland disbalance. Instead, the implementation of monoclonal antibodies therapeutic is useful to target cancer cells with diminishing toxicity and excessive specificity to health cells. For instance, in 2024, 22 latest fractional inhibitory concentration (FIC) drugs were approved by the FDA with a 44% proportion. Out of these, small molecule drugs nearly accounted for 10 drugs, and antibody drugs constituted 5 monoclonal antibodies and 3 bispecific antibodies.
- Risks associated with pituitary surgery: Endoscopic pituitary surgery is a stable process, but surgical procedures are at risk with reaction to anesthesia. Risks including cerebrospinal fluid rhinorrhea, meningitis, injury in the pituitary gland, diabetes insipidus, excessive bleeding, and visual difficulty lead to complications. For instance, transsphenoidal surgery is a complicated procedure among patients above 65 years, the complication rate being 32.6%. However, the rate is 33.2 % for overall age groups. Electrolyte abnormalities and fluid are prevailing complications, especially among 70 aged elders, creating a challenge in the pituitary cancer market.
Pituitary Cancer Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.8% |
|
Base Year Market Size (2024) |
USD 418.2 million |
|
Forecast Year Market Size (2037) |
USD 1.28 billion |
|
Regional Scope |
|
Pituitary Cancer Segmentation
Hormone Type (Gonadotropin-Secreting Tumor, Prolactinoma, Growth Hormone-Secreting Tumor {Acromegaly}, Adrenocorticotropic Hormone-Secreting Tumor {Cushing’s Disease}, Thyroid-Stimulating Hormone-Secreting Tumor {TSHoma})
In pituitary cancer market, gonadotropin-secreting tumor segment is set to capture revenue share of over 51.2% by 2037. The gonadotropin-secreting tumor produces follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The extreme presence of these hormones creates changes in menstrual circles, and fertility issues, and initiates pain in ovaries. As per a case study by NCBI 2024, a 42-year-old man suffered from a pituitary gland mass, and a 3 cm macroadenoma was revealed by a pituitary MRI. As a treatment, levothyroxine and hydrocortisone were provided along with surgical intervention which was delayed due to two negative results. Histopathology assessment was the ultimate diagnosis with constructive immunostaining for FSH, hence an optimistic approach towards the pituitary cancer market.
Cancer Type (Pituitary Adenomia {Benign Tumor}, Pituitary Carcinoma {Malignant Tumor})
Based on cancer type, the pituitary adenomia (benign tumor) segment in pituitary cancer market is projected to register a considerable share by 2037. This particular cancer type is classified into two categories- microadenomas (small than 10 mm and 1 cm) and macroadenomas (more than 10 mm). According to Barrow Neurological Institute, 10% of global population suffer from pituitary microadenoma and its subset prolactinomas are mostly diagnosed among women due to galactorrhea, amenorrhea, or both. In March 2024, Mayo Clinic used photon-counting detector CT to detect corticotroph adenomas and detected tumor in 8 patients. This visualization technique made improvement in tumor resection, ensuring surgery risks and long-term cure chances, hence driving the market growth.
Our in-depth analysis of the global pituitary cancer market includes the following segments:
|
Hormone Type |
|
|
Cancer Type |
|
|
Treatment Type |
|
|
Age Group |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPituitary Cancer Industry - Regional Synopsis
North America Market Statistics
North America pituitary cancer market is expected to dominate revenue share of over 41.7% by 2037. Advanced medical facilities, significant spending, and early recognition of treatment are factors driving the market upliftment in the region. According to the American Cancer Society 2022, over 10,000 pituitary tumors are identified every year in North America and most of these tumors are benign in type. Additionally, 1 in 4 people suffer from pituitary cancer without knowledge of it since it does not cause any health issues or symptoms.
The U.S. pituitary cancer market is witnessing significant exposure since this cancer type constitutes 10%-25% of intracranial neoplasms. The National Cancer Institute has classified pituitary tumors into three groups- benign tumors, invasive tumors, and carcinoma. Benign tumor caters the largest portion with an approximate 17% prevalence of pituitary neoplasms in the U.S. Medical or drug therapy including bromocriptine and cabergoline, somatostatin analogs, and ketoconazole are readily utilized to treat pituitary tumors. This therapy reduces blood prolactin levels and tumor size in more than 90% of patients and roughly 8%-10% of patients require radiation-based treatment.
The pituitary cancer market in Canada is growing since it is the leading cause of death in the region. As per the Canadian Cancer Statistics 2021, approximately 2 in 5 people are identified with cancer of which 1 in 4 die. For instance, ACTH-based pituitary tumors result in the occurrence of Cushing’s disease which requires transphenoidal exploration. Corticotropinomas are small in size and often not clearly visualized through MRI technique. However, the cure rate of pituitary tumors with the implementation of transsphenoidal surgery is 60%-80%. This ensures a rise in the market with focus on medical treatments in Canada. Besides, if this surgery results in failure, then pituitary radiation and bilateral adrenalectomy are alternate options for treatment.
Asia Pacific Market Analysis
The pituitary cancer market in Asia Pacific is gaining traction and is poised to witness considerable growth during the forecast period. Few pituitary cancers lead to hypopituitarism, neurologic dysfunction, and hormone hypersecretion, while some remain undetected due to the absence of symptoms. Overall, the prevalence rate of pituitary tumors ranges between 10% to 22% based on radiographic, autopsy, and indeed data. According to the Surveillance, Epidemiology, and End Results (SEER) database 2024, a study was conducted on 332 patients diagnosed with pituitary cancer from around the world between 2004 and 2019 and Asia Pacific Islanders were one of the nations covered. The survival rate was 86.8 %, 78.6 %, and 65.1 % based on 1, 5, and 10 years.
The pituitary cancer market in India is growing due to advanced exploration and management. As a developing country, India has moved forward with the latest discovery of treatment by adopting primary surgical intervention and residual tumor management by radiosurgery. The foremost surgical approach is transcranial surgery which is preferred by most neurosurgeons. Despite the advancement, the absolute resection for various types of pituitary cancer is 67%-70%, which is prevalent among tumors Knosp grade 3. Besides, the treatment cost of pituitary cancer is less in comparison to other nations, ranging between INR 50,000-70,000 (USD 725-1,015) for government centers and INR 200,000-250,000 (USD 2,900-3,620) for private centers.
Chronic psychological stress is the main cause of the rise in the pituitary cancer market in China. Stressors like anxiety, depression, isolation, and others trigger biological stress that activates the hypothalamic-pituitary-adrenocortical axis (HPA axis) and the sympathetic nervous system (SNS). To overcome this, traditional China medicines are incorporated such as Tai Chi, herbal medicine, and acupuncture therapy. Besides, the nation has focused on nutrition and diet counseling as the ultimate way to reduce the occurrence of malnutrition among patients suffering from malignant tumors, hence uplifting the market.
Companies Dominating the Pituitary Cancer Landscape
- Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ipsen Biopharmaceuticals, Inc.
- Accuracy Incorporated
- Corcept Therapeutics
- Cydan
- Camurus AB
- Varian Medical Systems
- Endocyte
- Camurus AB
- RECORDATI GROUP
Companies dominating the pituitary cancer market are rapidly gaining exposure based on the discovery of non-toxic chemicals devoid of man-made chemicals to produce medications that will ease tumors. In June 2024, Fortis Memorial Research Institute launched South Asia’s first-ever Gamma Knife Esprit for a high-precision and non-surgical treatment of brain tumors. The purpose was to enhance therapeutic alternatives for both benign and malignant tumors as well as any form of brain dysfunctionality.
Here's the list of some key players:
In the News
- In January 2025, Servier Pharmaceuticals announced the expansion of phase III of the Tibsovo (ivosidenib) Development Program to investigate the efficacy and safety among patients dealing with IDH1-mutated cancers in both solid tumors and hematological malignancies.
- In June 2023, Pfizer Inc. in association with OPKO Health Inc. declared the U.S. Food and Drug Administration (FDA) approval of NGENLA, a human development hormone analog for examining pediatric patients suffering from growth deficiency, thereby leading to tumor.
Author Credits: Radhika Pawar
- Report ID: 7069
- Published Date: Jan 29, 2025
- Report Format: PDF, PPT
